At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02617 TRANSTHERA-B
Market Closed 11-06 16:08:50
8.085
-0.260
-3.12%
High8.235
Low8.045
Vol2.45M
Open8.110
D1 Closing8.345
Amplitude2.28%
Mkt Cap3.30B
Tradable Cap2.53B
Total Shares408.00M
T/O19.91M
T/O Rate0.78%
Tradable Shares313.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
TRANSTHERA-B (02617) Spends HKD 454,600 to Repurchase 56,500 Shares on November 2
Transthera-B Doses First Patient in Phase II Trial of Tinengotinib Combined with Novel Endocrine Therapy for Advanced Metastatic Castration-Resistant Prostate Cancer in China
TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.